Clinical trial
The Efficacy and Safety of 7.2% NaCl Plus 6% Hydroxyethyl 200/0.5 in Patients Scheduled for First-time Coronary Artery Bypass Grafting With Cardiopulmonary Bypass.
NCT01675453 is registered in ClinicalTrials.gov with Meshalkin Research Institute of Pathology of Circulation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy and Safety of 7.2% NaCl Plus 6% Hydroxyethyl 200/0.5 in Patients Scheduled for First-time Coronary Artery Bypass Grafting With Cardiopulmonary Bypass.
- Lead sponsor
- Meshalkin Research Institute of Pathology of Circulation
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2012
- Completion date
- September 30, 2012
- Enrollment
- 40 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.